CTOR - Citius Oncology Inc. Company Long-Term Liabilities

Public company logo of Citius Oncology Inc. (CTOR)

The success of Citius Oncology, Inc. (CTOR) is based on the pace of bringing oncology drugs to market following its spin-off from the parent company. The market dynamics reflected in the price action show long-term debt amounting to 0.01. The company is currently focusing on launching a cutaneous lymphoma therapy and completing clinical stages. However, high certification costs and fierce industry competition create serious financial threats to the business's survival.

citiusonc.com (CTOR) Company Long-Term Debt: for the period 08/14/2024 - 10/30/2026

Citius Oncology, Inc (CTOR) - metric breakdowns and financial figures

- share price and expert price forecast:
Share Price citiusonc.com|CTOR - Analyst Consensus Forecast
- market capitalization statistics:
Market Valuation Citius Oncology|CTOR - Enterprise Value
- shareholders' equity book value data:
Net Asset Value per Share Citius Oncology|CTOR - Company Book Value|Market Value to Book Value citiusonc.com|CTOR - Cumulative Company Assets
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Citius Oncology, Inc.|CTOR - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Citius Oncology Inc|CTOR - Company Total Debt|Debts to Book Capitalization Citius Oncology|CTOR - Company Long-Term Debt|Company Short-Term Loans and Borrowings Citius Oncology|Immediate Liquidity citiusonc.com
- earnings and market multiples details:
CTOR - Net Profit
Fundamental company valuation:CTOR (citiusonc.com)
Brand item of Citius Oncology, Inc.

This indicator captures the total volume of credit obligations with maturities exceeding twelve months. By analyzing the size of the issuer's long-term liabilities, investors assess the balance between financial stability and expansion rates. For Citius Oncology, Inc. (CTOR), a stable debt level confirms the solvency required to complete drug development. In the future, strong pricing power in oncology will enable the efficient refinancing of these loans through premium revenue.

Competitors of Citius Oncology, Inc. (CTOR)

ONC: Company Long-Term Indebtedness|Halozyme - Company Long-Term Debts|Revolution Medicines Inc (RVMD) - Company Long-Term Liabilities|AAPG: Company Long-Term Debts|Long-Term Debt CG Oncology Therapeutics (CGON)|Company Long-Term Debt UroGen Pharma Ltd.|BCAX: Company Long-Term Loans and Borrowings|Company Long-Term Liabilities PSNL (Personalis)|ERAS (Erasca Inc) - Company Long-Term Loans and Borrowings|Company Long-Term Debts DCTH (Delcath)|YMAB - Company Long-Term Liabilities|AURA: Company Long-Term Liabilities|CADL - Company Long-Term Debts|Accuray (ARAY) - Company Long-Term Debt|SELLAS Life Sciences Group - Company Long-Term Loans and Borrowings|ACTU (Actuate Therapeutics, Inc) - Company Long-Term Debts|Long-Term Debt TuHURA HURA|Company Long-Term Debts TARA|Company Long-Term Liabilities fatetherapeutics.com FATE|Company Long-Term Debts WHWK (Aadi Bioscience)|Long-Term Debt Volume TScan Therapeutics Inc (TCRX)|CSBR: Company Long-Term Liabilities|XBiotech Inc. - Amount of Long-Term Liabilities|CVM: Company Long-Term Debts|OSTX - Long-Term Debt Volume|Company Long-Term Liabilities RADX|Company Long-Term Debts Artiva|Company Long-Term Debt Adlai Nortye Ltd. (ANL)|Long-Term Debt Volume Veru Corporation|Tempest Therapeutics - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings XLO|RENB - Company Long-Term Debt|Long-Term Debt Mural Oncology plc|kairospharma.com (KAPA) - Company Long-Term Debt|Company Long-Term Indebtedness OKUR|GDTC (CytoMed Therapeutics Ltd) - Company Long-Term Debts|Company Long-Term Liabilities Curis Corp (CRIS)|Company Long-Term Debt Apollomics, Inc. (APLM)|THAR - Long-Term Debt|Company Long-Term Debt Advanced Biomed ADVB|Genprex Inc - Company Long-Term Debt|CLDI - Company Long-Term Debt|Long-Term Debt Sunshine Biopharma Inc.|XBIO: Company Long-Term Debts|Long-Term Indebtedness Salarius Pharmaceuticals Inc SLRX|Company Long-Term Liabilities PPBT|Long-Term Debt AON AONC|Company Long-Term Liabilities BGNE (BeiGene, Ltd.)|CKPT (checkpointtx.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debts ELEV (Elevation Oncology, Inc.)|Long-Term Debt Volume iCAD Inc. (ICAD)|IKNA - Company Long-Term Debt|NTBL (Notable Labs Corp) - Company Long-Term Indebtedness|VIRX: Company Long-Term Debts|Company Long-Term Liabilities morphosys.com|Company Long-Term Liabilities NAYA|Ascentage Pharma Group International (AAPGV) - Long-Term Debt Volume